Dr. Luchi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
38th & Market St
8th Floor
Philadelphia, PA 19104Phone+1 215-662-4333
Education & Training
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 1987 - 1991
Northeast Ohio Medical UniversityClass of 1987
Certifications & Licensure
PA State Medical License 1992 - 2026
NJ State Medical License 1994 - 2001
NY State Medical License 1989 - 2000
American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease Start of enrollment: 2007 Sep 17
- A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis Start of enrollment: 2008 Oct 28
- INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs Start of enrollment: 2009 May 01
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsFRTX-02, a selective and potent inhibitor of DYRK1A, modulates inflammatory pathways in mouse models of psoriasis and atopic dermatitis.Soochan Kim, Eunhwa Ko, Hwan Geun Choi, Daekwon Kim, Monica Luchi
Journal of Translational Autoimmunity. 2023-01-01 - 4 citationsMRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.Charles Peterfy, Julie C DiCarlo, Paul Emery, Mark C. Genovese, Edward C. Keystone
The Journal of Rheumatology. 2019-01-15 - 214 citationsSafety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexateEdward C. Keystone, Peter C. Taylor, E. Drescher, Douglas E Schlichting, Scott D. Beattie
Annals of the Rheumatic Diseases. 2015-02-01
Press Mentions
Anti-Inflammatory Drugs Demonstrate Pathway SavvyJuly 7th, 2022- Chutes & Ladders—FDA's Top Two Vaccine Leaders to Depart in the Fall as Questions Loom over Booster ShotsSeptember 3rd, 2021
- Brickell Biotech Nabs Autoimmune, Inflammatory Program from Voronoi for up to $320M in BiobucksSeptember 1st, 2021
- Join now to see all
Other Languages
- Spanish, German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
